Reply: CD133 expression in different stages of gastric adenocarcinoma

por Smith, L M, Nesterova, A, Ryan, M C, Duniho, S, Jonas, M, Anderson, M, Sutherland, M K, Van Orden, K L, Moore, P A, Ruben, S M, Carter, P J
Publicado 2009

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75

por Ryan, M C, Kostner, H, Gordon, K A, Duniho, S, Sutherland, M K, Yu, C, Kim, K M, Nesterova, A, Anderson, M, McEarchern, J A, Law, C-L, Smith, L M
Publicado 2010

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

por Smith, L M, Nesterova, A, Ryan, M C, Duniho, S, Jonas, M, Anderson, M, Zabinski, R F, Sutherland, M K, Gerber, H-P, Van Orden, K L, Moore, P A, Ruben, S M, Carter, P J
Publicado 2008